Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition

Recruiting N/A Interventional Study
Melanoma (Skin Cancer)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
60 (estimated)
Sponsor
Charite University, Berlin, Germany · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The treatment of melanoma has improved significantly in recent years. A modern form of cancer treatment known as immunotherapy with checkpoint inhibitors plays a key role in this. These drugs help the immune system better recognize and fight cancer cells. Nevertheless, it remains a challenge to maximize treatment effectiveness while minimizing side effects. One possible approach to influencing tr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed stage IIB-IIIC melanoma * Indication for immune checkpoint inhibition as monotherapy as determined by the tumor board * No prior systemic melanoma therapy * ECOG 0 or 1 * ≥ 18 years of age Exclusion Criteria: * Pregnancy or breastfee…
Contacts

Anika Rajput, MD/PhD

004930450618599

melafit@charite.de

CONTACT

Thomas Eigentler, Prof. Dr.

CONTACT